Cargando…

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients

Extended thromboprophylaxis given to medically ill patients for up to 45 days following an acute hospitalization remains an emerging topic among many hospital-based health care providers. Recent advancements in the field of extended thromboprophylaxis using risk stratification and careful patient se...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacDougall, Kira, Spyropoulos, Alex C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230788/ https://www.ncbi.nlm.nih.gov/pubmed/32252423 http://dx.doi.org/10.3390/jcm9041002

Ejemplares similares

Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis
por: Coleman, Craig I., et al.
Publicado: (2020)

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis
por: Miao, Benjamin, et al.
Publicado: (2019)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
por: Raskob, Gary E., et al.
Publicado: (2021)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
por: Ferrandis, Raquel, et al.
Publicado: (2020)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Highlights: burden of venous thromboembolism and role of extended-duration thromboprophylaxis in acute medically ill patients
Publicado: (2018)

Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis
por: Ageno, Walter, et al.
Publicado: (2018)

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment
por: Al Yami, Majed S, et al.
Publicado: (2018)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

Adequate thromboprophylaxis in critically ill patients
por: Levi, Marcel
Publicado: (2010)

A new paradigm shift in antithrombotic therapy
por: Pudusseri, Anita, et al.
Publicado: (2013)

Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals
por: Martin, Anne-Céline, et al.
Publicado: (2019)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?
por: Rezende, Suely M., et al.
Publicado: (2023)

Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study
por: MacDougall, Kira, et al.
Publicado: (2020)

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study
por: Bottle, Alex, et al.
Publicado: (2015)

Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials
por: Kyriakoulis, Konstantinos G., et al.
Publicado: (2022)

What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?
por: Cauchie, Philippe, et al.
Publicado: (2021)

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study
por: Carvalho de Oliveira, Caroline Cândida, et al.
Publicado: (2023)

An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis
por: Forgo, Gabor, et al.
Publicado: (2021)

Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
por: Li, Guowei, et al.
Publicado: (2016)

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study
por: Tafur, Alfonso J., et al.
Publicado: (2020)

Dyscalculia, Dyslexia, and Medical Students’ Needs for Learning and Using Statistics
por: MacDougall, Margaret
Publicado: (2009)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Utilization of Ultrasound to Assess Volume Status in Heart Failure
por: Khan, Asif, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_76i9kc11rg0tps0lkmgs4fgsat